Abstract
Previous studies have implicated erythropoietin (EPO) signaling in the regulation of glucose metabolism. Whether EPO can be used to treat diabetes and the underlying mechanism remain to be elucidated. The present study aimed to investigate whether EPO affects glucose metabolism and the underlying mechanisms in experimental diabetic rats. The effects of EPO (300 U/kg three times a week for 4 weeks) on glucose metabolism, hematopoietic function, blood selenium content, and the ultrastructure of pancreatic β-cells were investigated in low-dose streptozotocin-induced experimental diabetic rats provided with a high-fat diet. The results demonstrated that EPO significantly decreased fasting blood glucose and the area under the curve of oral glucose tolerance and insulin tolerance tests. EPO also improved pancreatic β-cell damage by increasing anti-oxidation and blood selenium levels.
Introduction
Type 2 Diabetes Mellitus (T2DM) is characterized by insulin resistance and the progressive failure of pancreatic β-cells. While many therapeutic strategies target insulin sensitivity, protecting β-cells from oxidative stress and structural decay remains a significant challenge. Erythropoietin (EPO), a hormone primarily known for stimulating red blood cell production, has recently been found to have receptors in non-hematopoietic tissues, including the pancreas. This study investigates whether EPO can be repurposed to treat the metabolic and structural damage caused by T2DM.
Methods
Male Sprague Dawley rats were fed a high-fat diet and administered a low dose of streptozotocin (STZ) to induce diabetic symptoms. The rats were divided into three groups: Control, Diabetic Model, and EPO-treated (300 U/kg, three times weekly for four weeks). Metabolic health was assessed via Intraperitoneal Glucose Tolerance Tests (IPGTT), Insulin Tolerance Tests (ITT), and L-alanine gluconeogenesis tests. Additionally, the researchers performed ultrastructural analysis of β-cells using Transmission Electron Microscopy (TEM) and measured biochemical markers of oxidative stress (SOD, GSH-Px, and MDA) and blood selenium levels.
Results
Metabolic Improvements
EPO treatment led to a significant reduction in fasting blood glucose levels, dropping from approximately 24.4 mmol/l in the model group to 14.3 mmol/l in the treated group. The treatment also significantly improved the rats' ability to process glucose and respond to insulin, as evidenced by the reduced Area Under the Curve (AUC) in tolerance tests.
Structural and Biochemical Protection
Ultrastructural examination revealed that EPO physically restored pancreatic β-cells. While diabetic rats showed vacuolated cytoplasm and fragmented mitochondria, EPO-treated rats exhibited preserved mitochondrial cristae and an increased number of insulin-containing secretory granules. Furthermore, EPO treatment boosted blood selenium levels and increased the activity of antioxidant enzymes like Superoxide Dismutase (SOD), while decreasing Malondialdehyde (MDA), a marker of oxidative damage.
Discussion
The study suggests that EPO modulates glucose metabolism through a dual action: improving peripheral insulin sensitivity and reducing hepatic gluconeogenesis. The physical restoration of β-cells and the increase in blood selenium levels point to a novel antioxidant-driven cytoprotective pathway. However, the primary side effect of EPO treatment—erythrocytosis (excessive red blood cells)—remains a concern for clinical translation. Future research should focus on finding non-erythropoietic EPO derivatives or optimal metabolic-only dosages to mitigate risks like increased blood viscosity and hypertension.
Summary updated